


Curriculum Vitae

Name	Hye Ryun Kim, MD, PhD	
Current Position & Affiliation	Associate professor, Division of Medical Oncology, Yonsei Cancer Center, Yonsei University College of Medicine	
Country	KOREA	

Educational Background

1997-2001: Yonsei University College of Technology, department of biotechnology.
 2001-2005: Yonsei University College of Medicine, Seoul, Republic of Korea
 2007-2010: Master, Department of Medicine, Yonsei University College of Medicine
 2011-2015: Doctor of Philosophy, Department of Medicine, Graduate School of Yonsei University (Doctoral dissertation: The expression and function of PD-1 expressing regulatory T cells of cancer patients)

Professional Experience

2005-2006: Rotating internship, Severance Hospital, Seoul, Korea
 2006-2010: Resident in Internal Medicine, Severance Hospital, Seoul, Korea
 2010-2012: Clinical Fellowship, Division of Medical Oncology, Yonsei Cancer Center, Yonsei University College of Medicine.
 2012-2015: Clinical assistant professor, Division of Medical Oncology, Yonsei Cancer Center, Yonsei University College of Medicine.
 2016- 2019: Assistant professor, Division of Medical Oncology, Yonsei Cancer Center, Yonsei University College of Medicine.
 2020- current: Associate professor, Division of Medical Oncology, Yonsei Cancer Center, Yonsei University College of Medicine.

2014- 2018: Vice chief of Lung cancer center in Yonsei Cancer Center
 2016- current: Member of PRC (Protocol Review Committee) of KCSG
 2017- 2018: Administrator of lung cancer division of KCSG (Korean Cancer Study Group)
 2017- current: Member of IRB in Severance Hospital.
 2018- 2019: Chief of cancer informatics center in Yonsei Cancer Center
 2019 Mar - 2020 Jan: Visiting professor Emory University (in Prof. Rafi Ahmed LAB)

Professional Organizations

- 2012- American Society for Clinical Oncology 2010- Korean Cancer Study Group (KCSG)
2010- Korean Association for Clinical Oncology
2013- Korean Association for the Study of Lung Cancer
2013- The Korean Society for Head & Neck Oncology
2013- Active member of Lung Cancer and Head & Neck Cancer Committee of KCSG

Main Scientific Publications

1. Cho JW, Hong MH, Ha SJ, Kim YJ, Cho BC, Lee I, **Kim HR**. Genome-wide identification of differentially methylated promoters and enhancers associated with response to anti-PD-1 therapy in non-small cell lung cancer_ *Exp Mol Med* 2020 Sep 2 (**Correspondence**)
2. Son J, Cho JW, Park HJ, Moon J, Park S, Lee H, Lee J, Kim G, Park SM, Lira SA, McKenzie A, Kim HY, Choi CY, Lim YT, Park SY, **Kim HR**, Park SH, Shin EC, Lee I, Ha SJ. Tumor-Infiltrating Regulatory T Cell Accumulation in the Tumor Microenvironment is Mediated by IL33/ST2 Signaling *Cancer Immunol Res* 2020 Sep 2 (Co-author)
3. Lee YG, Kang EJ, Keam B, Choi JH, Kim JS, Park KU, Lee KE, Kwon JH, Lee KW, Kim MK, Ahn HK, Shin SH, Kim HR, Kim SB, Yun HJ. _ Treatment strategy and outcomes in locally advanced head and neck squamous cell carcinoma: a nationwide retrospective cohort study (KCSG HN13-01) *BMC Cancer*. 2020 Aug 27;20(1):813 (Co-author)
4. Kim CG, Kim C, Yoon SE, Kim KH, Choi SJ, Kang B, Kim HR, Park SH, Shin EC, Kim YY, Kim DJ, Chung HC, Chon HJ, Choi HJ, Lim HY Hyperprogressive disease during PD-1 blockade in patients with advanced hepatocellular carcinoma *J Hepatol*. 2020 Aug 15;S0168-8278 (Co-author)
5. Camidge DR, Kim HR, Ahn MJ, Yang JCH, Han JY, Hochmair MJ, Lee KH, Delmonte A, García Campelo MR, Kim DW, Griesinger F, Felip E, Califano R, Spira A, Gettinger SN, Tiseo M, Lin HM, Gupta N, Hanley MJ, Ni Q, Zhang P, Popat S. Brigatinib Versus Crizotinib in Advanced ALK Inhibitor-Naive ALK-Positive Non-Small Cell Lung Cancer: Second Interim Analysis of the Phase III ALTA-1L Trial *J Clin Oncol*. 2020 Aug 11:JCO2000505 (Co-author)

6. Hong MH, Heo SG, Lee YG, Kim HS, Park KU, Kim HG, Ko YH, Chung IJ, Min YJ, Kim MK, Kim KR, Yoo J, Kim TM, Kim HR, Cho BC. Phase 2 study of afatinib among patients with recurrent and/or metastatic esophageal squamous cell carcinoma *Cancer*. 2020 Aug 4 (**Correspondence**)
7. Pyo KH, Lim SM, Park CW, Jo HN, Kim JH, Yun MR, Kim D, Xin CF, Lee W, Gheorghiu B, Hong MH, Kim HR, Shim HS, Jang M, Lee SS, Cho BC. Comprehensive analyses of immunodynamics and immunoreactivity in response to treatment in ALK-positive non-small-cell lung cancer *J Immunother Cancer* 2020 Jul;8(2):e000970 (Co-author)
8. Park JH, Chun SH, Lee YG, Chang H, Lee KW, Kim HR, Shin SH, An HJ, Lee KE, Hwang IG, Ahn MJ, Kim SB, Keam B Hyperprogressive disease and its clinical impact in patients with recurrent and/or metastatic head and neck squamous cell carcinoma treated with immune-checkpoint inhibitors: Korean cancer study group HN 18-12 *J Cancer Res Clin Oncol*. 2020 Jul 15 (Co-author)
9. Chang H, Lee YG, Ko YH, Cho JH, Choi JK, Park KU, Kang EJ, Lee KW, Lim SM, Kim JS, Lee HW, Kim MK, Hwang IG, Kim S, Nam BH, **Kim HR**. Prognostic Value of CD200R1 mRNA Expression in Head and Neck Squamous Cell Carcinoma *Cancers (Basel)*. 2020 Jul 3;12(7):1777 (**Correspondence**)
10. Bo Ryeong Lee, Sehyun Chae, Jihyun Moon, Myeong Joon Kim, Hankyu Lee, Hyuk Wan Ko, Byoung Chul Cho, Hyo Sup Shim, Daehee Hwang, **Hye Ryun Kim**, and Sang-Jun Ha Combination of PD-L1 and PVR determines sensitivity to PD-1 blockade *JCI Insight*. 2020;5(14):e128633. (**Correspondence**)
11. Youn JI, Park SM, Park S, Kim G, Lee HJ, Son J, Hong MH, Ghaderpour A, Baik B, Islam J, Choi JW, Lee EY, Kim HR, Seo SU, Paik S, Yoon HI, Jung I, Xin CF, Jin HT, Cho BC, Seong SY, Ha SJ, **Kim HR**. Peripheral natural killer cells and myeloid-derived suppressor cells correlate with anti-PD-1 responses in non-small cell lung cancer *Sci Rep*. 2020 Jun 3;10(1):9050. (**Correspondence**)
12. Charles M. Rudin, Mark M. Awad, Alejandro Navarro, Maya Gottfried, Solange Peters, Tibor Csőszi, Parneet K. Cheema, Delvys Rodriguez-Abreu, Mirjana Wollner, James Chih-Hsin Yang, Julien Mazieres, Francisco J. Orlandi, Alexander Luft, Mahmut Gümüç, Terufumi Kato, Gregory P. Kalemkerian, Yiwen Luo, Victoria Ebiana, M. Catherine Pietanza, and **Hye Ryun Kim** Pembrolizumab or Placebo Plus Etoposide and Platinum as First-Line Therapy for Extensive-Stage Small-Cell Lung Cancer: Randomized, Double-Blind, Phase III KEYNOTE-604 Study (**senior author**) **JCO.20.00793 Journal of Clinical Oncology**

13. Yun J, Lee SH, Kim SY, Jeong SY, Kim JH, Pyo KH, Park CW, Heo SG, Yun MR, Lim S, Lim SM, Hong MH, **Kim HR**, Thayu M, Curtin JC, Knoblauch RE, Lorenzi MV, Roshak A, Cho BC Antitumor Activity of Amivantamab (JNJ-61186372), an EGFR-MET Bispecific Antibody, in Diverse Models of EGFR Exon 20 Insertion-Driven NSCLC Cancer Discov. 2020 Aug;10(8):1194-1209
14. Yun MR, Kim DH, Kim SY, Joo HS, Lee YW, Choi HM, Park CW, Heo SG, Kang HN, Lee SS, Schoenfeld AJ, Drilon A, Kang SG, Shim HS, Hong MH, Cui JJ, **Kim HR**, Cho BC Repotrectinib Exhibits Potent Antitumor Activity in Treatment-Naïve and Solvent-Front-Mutant ROS1-Rearranged Non-Small Cell Lung Cancer Clin Cancer Res. 2020 Jul 1;26(13):3287-3295 **(Correspondence)**
15. Cho J, Lee HJ, Hwang SJ, Min HY, Kang HN, Park AY, Hyun SY, Sim JY, Lee HJ, Jang HJ, Suh YA, Hong S, Shin YK, **Kim HR**, Lee HY. The Interplay between Slow-Cycling, Chemoresistant Cancer Cells and Fibroblasts Creates a Proinflammatory Niche for Tumor Progression Cancer Res. 2020 Jun 1;80(11):2257-2272 **(Correspondence)**
16. Lim SM, Hong MH, **Kim HR** Immunotherapy for Non-small Cell Lung Cancer: Current Landscape and Future Perspectives Immune Netw. 2020 Jan 27;20(1):e10. **(Correspondence)**
17. Kim K, Park S, Park SY, Kim G, Park SM, Cho JW, Kim DH, Park YM, Koh YW, Kim HR, Ha SJ, Lee I. Single-cell transcriptome analysis reveals TOX as a promoting factor for T cell exhaustion and a predictor for anti-PD-1 responses in human cancer Genome Med. 2020 Feb 28;12(1):22
18. Kim CG, Kim KH, Pyo KH, Xin CF, Hong MH, Ahn BC, Kim Y, Choi SJ, Yoon HI, Lee JG, Lee CY, Park SY, Park SH, Cho BC, Shim HS, Shin EC, **Kim HR**. Hyperprogressive disease during PD-1/PD-L1 blockade in patients with non-small-cell lung cancer. **Ann Oncol. 2019 Jul 1;30(7):1104-1113 (Correspondence)**
19. **Kim HR**, Park HJ, Son J, Lee JG, Chung KY, Cho NH, Shim HS, Park S, Kim G, In Yoon H, Kim HG, Jung YW, Cho BC, Park SY, Rha SY, Ha SJ. Tumor microenvironment dictates regulatory T cell phenotype: Upregulated immune checkpoints reinforce suppressive function. **J Immunother Cancer. 2019 Dec 4;7(1):339. (First author)**
20. Hong MH, Shin SJ, Shin SK, Kim DJ, Zo JI, Shim YM, Lee SE, Cho BC, Park SY, Choi YL, **Kim HR** High CD3 and ICOS and low TIM-3 expression predict favourable survival in resected oesophageal squamous cell carcinoma. **Sci Rep. 2019 Dec 27;9(1):20197 (Correspondence)**

21. Kim SY, Lee JY, Kim DH, Joo H-, Yun MR, Jung D, Yun J, Heo SG, Ahn B-, Park CW, Pyo KH, Chun YJ, Hong MH, **Kim HR**, Cho BC. Patient-Derived Cells to Guide Targeted Therapy for Advanced Lung Adenocarcinoma. **Sci Rep. 2019 Dec 27;9(1):19909. (Co-correspondence)**
22. Na KJ, Hyun K, Kang CH, Park S, Lee HJ, Park IK, Kim YT, Lee GD, **Kim HR**, Choi SH, Kim YH, Kim DK, Park SI, Shin S, Cho JH, Kim HK, Choi YS, Kim J, Zo JI, Shim YM, Lee CY, Lee JG, Kim DJ, Paik HC, Chung KY. Predictors of post-thymectomy long-term neurological remission in thymomatous myasthenia gravis: an analysis from a multi-institutional database. **Eur J Cardiothorac Surg. 2019 Dec 20**
23. Chun YJ, Choi JW, Hong MH, Jung D, Son H, Cho EK, Min YJ, Kim SW, Park K, Lee SS, Kim S, **Kim HR**, Cho BC; Korean Lung Cancer Consortium (KLCC). Molecular characterization of lung adenocarcinoma from Korean patients using next generation sequencing. **PLoS One. 2019 Nov 25;14(11):e0224379 (Co-correspondence)**
24. Yun MR, Choi HM, Lee YW, Joo HS, Park CW, Choi JW, Kim DH, Kang HN, Pyo KH, Shin EJ, Shim HS, Soo RA, Yang JC, Lee SS, Chang H, Kim MH, Hong MH, **Kim HR**, Cho BC. Targeting YAP to overcome acquired resistance to ALK inhibitors in ALK-rearranged lung cancer. **EMBO Mol Med. 2019 Dec;11(12):e10581**
25. Ahn MJ, Han JY, Lee KH, Kim SW, Kim DW, Lee YG, Cho EK, Kim JH, Lee GW, Lee JS, Min YJ, Kim JS, Lee SS, **Kim HR**, Hong MH, Ahn JS, Sun JM, Kim HT, Lee DH, Kim S, Cho BC. Lazertinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: results from the dose escalation and dose expansion parts of a first-in-human, open-label, multicentre, phase 1-2 study. **Lancet Oncol. 2019 Dec;20(12):1681-1690**
26. Cho Y, Park S, Byun HK, Lee CG, Cho J, Hong MH, **Kim HR**, Cho BC, Kim S, Park J, Yoon HI. Impact of Treatment-Related Lymphopenia on Immunotherapy for Advanced Non-Small Cell Lung Cancer. **Int J Radiat Oncol Biol Phys. 2019 Dec 1;105(5):1065-1073**
27. Choe EA, Cha YJ, Kim JH, Pyo KH, Hong MH, Park SY, Shim HS, Jung I, Lee CY, Cho BC, **Kim HR** Dynamic changes in PD-L1 expression and CD8+ T cell infiltration in non-small cell lung cancer following chemoradiation therapy. **Lung Cancer 2019 Oct**
28. Park JS, Hong MH, Chun YJ, **Kim HR**, Cho BC. A phase Ib study of the combination of afatinib and ruxolitinib in EGFR mutant NSCLC with progression on EGFR-TKIs. **Lung Cancer 2019 Aug**
29. Kim G, Yoo M, Hong MH, Lee BW, Kang ES, Cha BS, **Kim HR***, Lee YH, Cho BC. Predictive factors for the development of diabetes in cancer patients treated with phosphatidylinositol 3-kinase inhibitors. **Cancer Chemother Pharmacol. 2019 Aug (Co-correspondence)**

30. Hong MH, **Kim HR**, Ahn BC, Heo SJ, Kim JH, Cho BC. Real-World Analysis of the Efficacy of Rebiopsy and EGFR Mutation Test of Tissue and Plasma Samples in Drug-Resistant Non-Small Cell Lung Cancer. **Yonsei Med J. 2019 Jun**
31. Lim SM, Choi JW, Hong MH, Jung D, Lee CY, Park SY, Shim HS, Sheen S, Kwak KI, Kang DR, Cho BC, **Kim HR**. Indoor radon exposure increases tumor mutation burden in never-smoker patients with lung adenocarcinoma. **Lung Cancer. 2019 May (Correspondence)**
32. Yun JK, Lee GD, **Kim HR**, Kim DK, Zo JI, Shim YM, Kang CH, Kim YT, Paik HC, Chung KY; other members of the Korean Association for Research on the Thymus (KART). A nomogram for predicting recurrence after complete resection for thymic epithelial tumors based on the TNM classification: A multi-institutional retrospective analysis. **J Surg Oncol. 2019 Jun**
33. Ahn BC, Pyo KH, Xin CF, Jung D, Shim HS, Lee CY, Park SY, Yoon HI, Hong MH, Cho BC, **Kim HR** Comprehensive analysis of the characteristics and treatment outcomes of patients with non-small cell lung cancer treated with anti-PD-1 therapy in real-world practice. **J Cancer Res Clin Oncol. 2019 July**
34. Levy B, Paz-Ares L, Bennouna J, Felip E, Abreu DR, Isla D, Barlesi F, Molinier O, Madelaine J, Audigier-Valette C, Kim SW, **Kim HR**, Ozguroglu M, Erman M, Badin FB, Mekhail TM, Scheff R, Chisamore MJ, Sadrolhefazi B, Riess JW. Afatinib With Pembrolizumab for Treatment of Patients With Locally Advanced/Metastatic Squamous Cell Carcinoma of the Lung: The LUX-Lung IO/KEYNOTE 497 Study Protocol. **Clin Lung Cancer. 2019 May**
35. Yun J, Hong MH, Kim SY, Park CW, Kim S, Yun MR, Kang HN, Pyo KH, Lee SS, Koh JS, Song HJ, Kim DK, Lee YS, Oh SW, Choi S, **Kim HR***, Cho BC YH25448, an Irreversible EGFR-TKI with Potent Intracranial Activity in EGFR Mutant Non-Small Cell Lung Cancer. **Clin Cancer Res. 2019 Apr (Co- Correspondence)**
36. **Kim HR***, Park SM, Seo SU, Jung I, Yoon HI, Gabrilovich DI, Cho BC, Seong SY, Ha SJ, Youn JI. The Ratio of Peripheral Regulatory T Cells to Lox-1+ Polymorphonuclear Myeloid-derived Suppressor Cells Predicts the Early Response to Anti-PD-1 Therapy in Patients with Non-Small Cell Lung Cancer. **Am J Respir Crit Care Med. 2019 (Co-correspondence)**

37. Camidge DR, **Kim HR**, Ahn MJ, Yang JC, Han JY, Lee JS, Hochmair MJ, Li JY, Chang GC, Lee KH, Gridelli C, Delmonte A, Garcia Campelo R, Kim DW, Bearz A, Griesinger F, Morabito A, Felip E, Califano R, Ghosh S, Spira A, Gettinger SN, Tiseo M, Gupta N, Haney J, Kerstein D, Popat S. Brigatinib versus Crizotinib in ALK-Positive Non-Small-Cell Lung Cancer. **N Engl J Med. 2018 Nov**
38. Kang HN, Choi JW, Shim HS, Kim J, Kim DJ, Lee CY, Hong MH, Park SY, Park AY, Shin EJ, Lee SY, Pyo KH, Yun MR, Choi HM, Lee SS, Kim SY, Lee H, Paik S, Cho BC, Lee JG, Kim HR. Establishment of a platform of non-small-cell lung cancer patient-derived xenografts with clinical and genomic annotation. Kang HN, Choi JW, Shim HS, Kim J, Kim DJ, Lee CY, Hong MH, Park SY, Park AY, Shin EJ, Lee SY, Pyo KH, Yun MR, Choi HM, Lee SS, Kim SY, Lee H, Paik S, Cho BC, Lee JG, **Kim HR***. **Lung Cancer. 2018 Oct (Correspondence)**
39. Hwang Y, Kang CH, Park S, Lee HJ, Park IK, Kim YT, Lee GD, **Kim HR**, Choi SH, Kim YH, Kim DK, Park SI, Shin S, Cho JH, Kim HK, Choi YS, Kim J, Zo JI, Shim YM, Lee CY, Lee JG, Kim DJ, Paik HC, Chung KY. Impact of Lymph Node Dissection on Thymic Malignancies: Multi-Institutional Propensity Score Matched Analysis. **J Thorac Oncol. 2018 Dec**
40. Yoo KH, Lee SJ, Cho J, Lee KH, Park KU, Kim KH, Cho EK, Choi YH, **Kim HR**, Kim HG, Ahn HJ, Lee HY, Yun HJ, Kang JH, Jeong J, Choi MY, Jung SH, Sun JM, Lee SH, Ahn JS, Park K, Ahn MJ. A Randomized, Open-Label, Phase II Study Comparing Pemetrexed Plus Cisplatin Followed by Maintenance Pemetrexed versus Pemetrexed Alone in Patients with Epidermal Growth Factor Receptor (EGFR)- Mutant Non-small Cell Lung Cancer after Failure of First-Line EGFR Tyrosine Kinase Inhibitor: KCSG- LU12-13. **Cancer Res Treat. 2018**
41. Keam B, **Kim HR**, Yun HJ. TRIUMPH Trial: One Small Step Could Become One Giant Leap for Precision Oncology in Head and Neck Cancer. **Cancer Res Treat. 2019**
42. Wu YL, Ahn MJ, Garassino MC, Han JY, Katakami N, **Kim HR**, Hodge R, Kaur P, Brown AP, Ghiorghiu D, Papadimitrakopoulou VA, Mok TSK. CNS Efficacy of Osimertinib in Patients With T790M-Positive Advanced Non-Small-Cell Lung Cancer: Data From a Randomized Phase III Trial (AURA3). **J Clin Oncol. 2018 Sep 10**
43. Choi JR, Koh SB, **Kim HR**, Lee H, Kang DR Radon Exposure-induced Genetic Variations in Lung Cancers among Never Smokers. **J Korean Med Sci. 2018**

44. Park S, Ahn BC, Lim SW, Sun JM, Kim HR, Hong MH, Lee SH, Ahn JS, Park K, Choi Y, Cho BC, Ahn MJ. Characteristics and Outcome of ROS1-Positive Non-Small Cell Lung Cancer Patients in Routine Clinical Practice. **J Thorac Oncol. 2018**
45. Lim SM, Cho SH, Hwang IG, Choi JW, Chang H, Ahn MJ, Park KU, Kim JW, Ko YH, Ahn HK, Cho BC, Nam BH, Chun SH, Hong JH, Kwon JH, Choi JG, Kang EJ, Yun T, Lee KW, Kim JH, Kim JS, Lee HW, Kim MK, Jung D, Kim JE, Keam B, Yun HJ, Kim S, **Kim HR** Investigating the Feasibility of Targeted Next- Generation Sequencing to Guide the Treatment of Head and Neck Squamous Cell Carcinoma. *Cancer Res Treat.* 2019 (**Correspondence**)
46. Vishwanathan K, Dickinson PA, So K, Thomas K, Chen YM, De Castro Carpeño J, Dingemans AC, **Kim HR**, Kim JH, Krebs MG, Chih-Hsin Yang J, Bui K, Weilert D, Harvey RD. The effect of itraconazole and rifampicin on the pharmacokinetics of osimertinib. **Br J Clin Pharmacol. 2018**
47. Choi JR, Koh SB, Park SY, **Kim HR**, Lee H, Kang DR Novel Genetic Associations Between Lung Cancer and Indoor Radon Exposure. **J Cancer Prev. 2017**
48. Lim SM*, **Kim HR***, Lee JS, Lee KH, Lee YG, Min YJ, Cho EK, Lee SS, Kim BS, Choi MY, Shim HS, Chung JH, La Choi Y, Lee MJ, Kim M, Kim JH, Ali SM, Ahn MJ, Cho BC. Open-Label, Multicenter, Phase II Study of Ceritinib in Patients With Non-Small-Cell Lung Cancer Harboring ROS1 Rearrangement. **J Clin Oncol. 2017 (Co-first author)**
49. **Kim HR**, Kang HN, Shim HS, Kim EY, Kim J, Kim DJ, Lee JG, Lee CY, Hong MH, Kim SM, Kim H, Pyo KH, Yun MR, Park HJ, Han JY, Youn HA, Ahn MJ, Paik S, Kim TM, Cho BC. Co-clinical trials demonstrate predictive biomarkers for dovitinib, an FGFR inhibitor, in lung squamous cell carcinoma. **Ann Oncol. 2017**
50. Soo RA*, **Kim HR***, Asuncion BR, Fazreen Z, Omar MF, Herrera MC, Yun Lim JS, Sia G, Soong R, Cho BC. Significance of immune checkpoint proteins in EGFR-mutant non-small cell lung cancer. **Lung Cancer. 2017 Mar (Co-first author)**
51. **Kim HR**, Ha SJ, Hong MH, Heo SJ, Koh YW, Choi EC, Kim EK, Pyo KH, Jung I, Seo D, Choi J, Cho BC, Yoon SO. PD-L1 expression on immune cells, but not on tumor cells, is a favorable prognostic factor for head and neck cancer patients. **Sci Rep. 2016**
52. **Hye Ryun Kim**, Kyung Hae Jung, Seock-Ah Im, Young-Hyuck Im, Seok Yun Kang, Kyong Hwa Park, Soohyeon Lee, Sung-Bae Kim, Kyung-Hun Lee, Jin Seok Ahn, Seung Il Kim, Joohyuk Sohn. Multicentre phase II trial of bevacizumab combined with docetaxel plus carboplatin for the neoadjuvant treatment of triple-negative breast cancer (KCSG BR-0905) **Annals of Oncology 2013**

53. **Hye Ryun Kim**, Dae Joon Kim, Dae Ryong Kang, Jin Gu Lee, Sun Min Lim, Chang Young Lee, Sun Young Rha, Mi Kyung Bae, Young Joo Lee, Se Hoon Kim, Sang-Jun Ha, Ross Soo, Kyung Young Chung, Joo Hang Kim, Ji Hyun Lee, Hyo Sup Shim and Byoung Chul Cho. Fibroblast Growth Factor Receptor 1 Gene Amplification Is Associated with Poor Survival and Cigarette Smoking Dosage in Resected Squamous Cell Lung Cancer Patients. **J Clinic Oncol** 2012
54. **Kim HR**, Cha YJ, Hong MH, Gandhi M, Levinson S, Jung I, Lee JG, Lee CY, Cho BC, Ha SJ, Shim HS. Concordance of programmed death-ligand 1 expression between primary and metastatic non-small cell lung cancer by immunohistochemistry and RNA in situ hybridization. **Oncotarget**. 2017
55. Mok TS, Wu YL, Ahn MJ, Garassino MC, **Kim HR**, Ramalingam SS, Shepherd FA, He Y, Akamatsu H, Theelen WS, Lee CK, Sebastian M, Templeton A, Mann H, Marotti M, Ghiorghiu S, Papadimitrakopoulou VA; AURA3 Investigators. Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer. **N Engl J Med**. 2016
56. Vishwanathan K, Dickinson PA, So K, Thomas K, Chen YM, De Castro Carpeño J, Dingemans AC, **Kim HR**, Kim JH, Krebs MG, Chih-Hsin Yang J, Bui K, Weilert D, Harvey RD. The effect of itraconazole and rifampicin on the pharmacokinetics of osimertinib. **Br J Clin Pharmacol**. 2018
57. Choi JR, Koh SB, Park SY, **Kim HR**, Lee H, Kang DR. Novel Genetic Associations Between Lung Cancer and Indoor Radon Exposure. **J Cancer Prev**. 2017 Dec;22(4):234-240.
58. Park S, Cho Y, Lee J, Koh YW, Kim SH, Choi EC, **Kim HR**, Keum KC, Park KR, Lee CG. Survival and Functional Outcome after Treatment for Primary Base of Tongue Cancer: A Comparison of Definitive Chemoradiotherapy versus Surgery Followed by Adjuvant Radiotherapy. **Cancer Res Treat**. 2017
59. Park YM, **Kim HR**, Cho BC, Keum KC, Cho NH, Kim SH. Transoral robotic surgery-based therapy in patients with stage III-IV oropharyngeal squamous cell carcinoma. **Oral Oncol**. 2017
60. Lee CK, Kim S, Lee JS, Lee JE, Kim SM, Yang IS, **Kim HR**, Lee JH, Kim S, Cho BC. Next-generation sequencing reveals novel resistance mechanisms and molecular heterogeneity in EGFR-mutant non-small cell lung cancer with acquired resistance to EGFR-TKIs. **Lung Cancer**. 2017
61. Park YM, Keum KC, **Kim HR**, Cho BC, Kim DH, Cho NH, Kim SH. A Clinical Trial of Combination Neoadjuvant Chemotherapy and Transoral Robotic Surgery in Patients with T3 and T4 Laryngo-Hypopharyngeal Cancer. **Ann Surg Oncol**. 2018

62. Ahn MJ, Kim DW, Cho BC, Kim SW, Lee JS, Ahn JS, Kim TM, Lin CC, **Kim HR**, John T, Kao S, Goldman JW, Su WC, Natale R, Rabbie S, Harrop B, Overend P, Yang Z, Yang JC. Activity and safety of AZD3759 in EGFR-mutant non-small-cell lung cancer with CNS metastases (BLOOM): a phase 1, open-label, dose-escalation and dose-expansion study. **Lancet Respir Med** 2017
63. Hong MH, Kim CG, Koh YW, Choi EC, Kim J, Yoon SO, **Kim HR**, Cho BC. Efficacy and safety of vinorelbine plus cisplatin chemotherapy for patients with recurrent and/or metastatic salivary gland cancer of the head and neck. **Head Neck**. 2018 (Co-correspondence)
64. Ryu HJ, Kim EK, Heo SJ, Cho BC, **Kim HR**, Yoon SO. Architectural patterns of p16 immunohistochemical expression associated with cancer immunity and prognosis of head and neck squamous cell carcinoma. **APMIS**. 2017
65. Yun MR, Choi HM, Kang HN, Lee Y, Joo HS, Kim DH, **Kim HR**, Hong MH, Yoon SO, Cho BC ERK- dependent IL-6 autocrine signaling mediates adaptive resistance to pan-PI3K inhibitor BKM120 in head and neck squamous cell carcinoma. **Oncogene**. 2017
66. Lim SM, Chang H, Cha YJ, Liang S, Tai YC, Li G, Pestova E, Policht F, Perez T, Soo RA, Park WY, **Kim HR**, Shim HS, Cho BC. Validation of ALK/ROS1 Dual Break Apart FISH Probe probe in non-small-cell lung cancer. **Lung Cancer**. 2017
67. Park YM, Jung CM, Cha D, Kim DH, **Kim HR**, Keum KC, Cho NH, Kim SH. A New Clinical Trial of Neoadjuvant Chemotherapy Combined With Transoral Robotic Surgery and Customized Adjuvant Therapy for Patients With T3 or T4 Oropharyngeal Cancer. **Ann Surg Oncol**. 2017
68. Chung SY, Chang JH, **Kim HR**, Cho BC, Lee CG, Suh CO. Optimal dose and volume for postoperative radiotherapy in brain oligometastases from lung cancer: a retrospective study. **Radiat Oncol J**. 2017
69. Kim CG, Shim HS, Hong MH, Cha YJ, Heo SJ, Park HS, Kim JH, Lee JG, Lee CY, Cho BC, **Kim HR**. Detection of activating and acquired resistant mutation in plasma from EGFR-mutated NSCLC patients by peptide nucleic acid (PNA) clamping-assisted fluorescence melting curve analysis. **Oncotarget**. 2017
70. Kim GM, Kim SJ, Song SK, **Kim HR**, Kang BD, Noh SH, Chung HC, Kim KR, Rha SY. Prevalence and prognostic implications of psychological distress in patients with gastric cancer. **BMC Cancer**. 2017 Apr 20;17(1):283
71. Rydén A, Blackhall F, **Kim HR**, Pillai RN, Braam L, Martin ML, Walding A. Patient Experience of Symptoms and Side Effects when Treated with Osimertinib for Advanced Non-Small-Cell Lung Cancer: A Qualitative Interview Substudy. **Patient**. 2017

72. Rha SY, Sohn J, Kim GM, **Kim HR**, Lee J The Benefit of Pro Re Nata Antiemetics Provided With Guideline-Consistent Antiemetics in Delayed Nausea Control. **Cancer Nurs. 2017**
73. Kim Y, Lee SJ, Lee JY, Lee SH, Sun JM, Park K, An HJ, Cho JY, Kang EJ, Lee HY, Kim J, Keam B, **Kim HR**, Lee KE, Choi MY, Lee KH, Ahn MJ. Clinical trial of nintedanib in patients with recurrent or metastatic salivary gland cancer of the head and neck: A multicenter phase 2 study (Korean Cancer Study Group HN14-01). **Cancer. 2017**
74. Na YC, Jung HH, **Kim HR**, Cho BC, Chang JW, Park YG, Chang WS. **J Neurooncol. 2017** Apr;132(2):333-340. Predictive factors of early distant brain failure after gamma knife radiosurgery alone in patients with brain metastases of non-small-cell lung cancer.
75. Cho YA, Kim EK, Heo SJ, Cho BC, **Kim HR**, Chung JM, Yoon SO. Alteration status and prognostic value of MET in head and neck squamous cell carcinoma. **J Cancer. 2016**
76. Cha YJ, **Kim HR**, Lee HJ, Cho BC, Shim HS. Clinical course of stage IV invasive mucinous adenocarcinoma of the lung. **Lung Cancer. 2016**
77. Pyo KH, Lim SM, **Kim HR**, Sung YH, Yun MR, Kim SM, Kim H, Kang HN, Lee JM, Kim SG, Park CW, Chang H, Shim HS, Lee HW, Cho BC. Establishment of a Conditional Transgenic Mouse Model Recapitulating EML4-ALK-Positive Human Non-Small Cell Lung Cancer. **J Thorac Oncol. 2016**
78. Cha YJ, **Kim HR**, Shim HS. Clinical outcomes in ALK-rearranged lung adenocarcinomas according to ALK fusion variants. **J Transl Med. 2016**
79. **Kim HR**, Jang JS, Sun JM, Ahn MJ, Kim DW, Jung I, Lee KH, Kim JH, Lee DH, Kim SW, Cho BC. A randomized, phase II study of gefitinib alone versus nimotuzumab plus gefitinib after platinum- based chemotherapy in advanced non-small cell lung cancer (KCSG LU12-01). **Oncotarget. 2016**
80. Kim SM, Kim H, Yun MR, Kang HN, Pyo KH, Park HJ, Lee JM, Choi HM, Ellinghaus P, Ocker M, Paik S, **Kim HR***, Cho BC*. Activation of the Met kinase confers acquired drug resistance in FGFR-targeted lung cancer therapy. **Oncogenesis. 2016 (Co-correspondence)**
81. Lim SH, Sun JM, Choi YL, **Kim HR**, Ahn S, Lee JY, Lee SH, Ahn JS, Park K, Kim JH, Cho BC, Ahn MJ. Efficacy and safety of dovitinib in pretreated patients with advanced squamous non-small cell lung cancer with FGFR1 amplification: A single-arm, phase 2 study. **Cancer. 2016**

82. Cha YJ, **Kim HR**, Lee CY, Cho BC, Shim HS. Clinicopathological and prognostic significance of programmed cell death ligand-1 expression in lung adenocarcinoma and its relationship with p53 status. **Lung Cancer. 2016.**
83. Lim SM*, **Kim HR***, Cho EK, Min YJ, Ahn JS, Ahn MJ, Park K, Cho BC, Lee JH, Jeong HC, Kim EK, Kim JH. Targeted sequencing identifies genetic alterations that confer primary resistance to EGFR tyrosine kinase inhibitor (Korean Lung Cancer Consortium). **Oncotarget. 2016 (Co-first author)**
84. Park HS, Lim SM, Kim S, Kim S, **Kim HR**, Kwack K, Lee MG, Kim JH, Moon YW. Pilot Study of a Next- Generation Sequencing-Based Targeted Anticancer Therapy in Refractory Solid Tumors at a Korean Institution. **PLoS One. 2016**
85. Kim HS, Lee SE, Bae YS, Kim DJ, Lee CG, Hur J, Chung H, Park JC, Shin SK, Lee SK, Lee YC, **Kim HR**, Shim YM, Jewell SS, Kim H, Choi YL, Cho BC. PIK3CA amplification is associated with poor prognosis among patients with curatively resected esophageal squamous cell carcinoma. **Oncotarget. 2016**
86. **Kim HR**, Kim JH, Rhee Y, Lee H, Song SE, Kim C, Song S, Noh SH, Rha SY. Assessment of Adrenal Function and Health-Related Quality of Life in Advanced Gastric Cancer Patients Who Received First-Line Chemotherapy. **Oncology. 2016**
87. Kang HN, Kim SH, Yun MR, **Kim HR**, Lim SM, Kim MS, Hong KW, Kim SM, Kim H, Pyo KH, Park HJ, Han JY, Youn HA, Chang KH, Cho BC. ER2, a novel human anti-EGFR monoclonal antibody inhibit tumor activity in non-small cell lung cancer models. **Lung Cancer. 2016**
88. Lim SM, Kim EY, **Kim HR**, Ali SM, Greenbowe JR, Shim HS, Chang H, Lim S, Paik S, Cho BC. Genomic profiling of lung adenocarcinoma patients reveals therapeutic targets and confers clinical benefit when standard molecular testing is negative. **Oncotarget. 2016**
89. **Kim HR**, Lee CG, Choi EC, Kim JH, Koh YW, Cho BC. Induction docetaxel and S-1 followed by concomitant radiotherapy with low-dose daily cisplatin in locally advanced head and neck carcinoma. **Head Neck. 2016**
90. Hong N, Yoon HJ, Lee YH, **Kim HR**, Lee BW, Rhee Y, Kang ES, Cha BS, Lee HC. Serum PTHrP Predicts Weight Loss in Cancer Patients Independent of Hypercalcemia, Inflammation, and Tumor Burden. **J Clin Endocrinol Metab. 2016**

91. Lee JY, Qing X, Xiumin W, Yali B, Chi S, Bak SH, Lee HY, Sun JM, Lee SH, Ahn JS, Cho EK, Kim DW, **Kim HR**, Min YJ, Jung SH, Park K, Mao M, Ahn MJ. Longitudinal monitoring of EGFR mutations in plasma predicts outcomes of NSCLC patients treated with EGFR TKIs: Korean Lung Cancer Consortium (KLCC-12-02). **Oncotarget. 2016**
92. Cha YJ, Cho BC, **Kim HR**, Lee HJ, Shim HS. A Case of ALK-Rearranged Adenocarcinoma with Small Cell Carcinoma-Like Transformation and Resistance to Crizotinib. **J Thorac Oncol. 2016**
93. Park HS, Lim SM, Shin HJ, Cho A, Shin JG, Lee MG, **Kim HR**, Kim JH, Cho BC. Pharmacogenetic analysis of advanced non-small-cell lung cancer patients treated with first-line paclitaxel and carboplatin chemotherapy. **Pharmacogenet Genomics. 2016**
94. Sung-Moo Kim, Hwan Kim, Min Hwan Kim, Jinyoung Sohn, Mi Ran Yun, Han Na Kang¹, Chan Woo Kang, **Hye Ryun Kim**, Sun Min Lim, Yong Wha Moon, Soonmyung Paik, and Byoung Chul Cho. EGFR-mediated activation of RIP-2 induces acquired resistance to GSK2118436 in BRAF V600E mutant non-small cell lung cancer. **Mol Cancer Ther 2016.**
95. Next-generation sequencing reveals somatic mutations that confer exceptional response to everolimus. Sun Min Lim, Hyung Soon Park, Sangwoo Kim, Sora Kim, Siraj. M. Ali, Joel. R. Greenbowe, In Seok Yang, Nak-Jung Kwon, Jae Lyun Lee, Min-Hee Ryu, Jin-Hee Ahn, Jeeyun Lee, Min Goo Lee, Hyo Song Kim, Hyunki Kim, **Hye Ryun Kim**, Yong Wha Moon, Hyun Cheol Chung, Joo- Hang Kim, Yoon-Koo Kang and Byoung Chul Cho. **Oncotarget 2016.**
96. A randomized phase II trial of ERCC1 and RRM1 mRNA expression-based chemotherapy versus docetaxel/carboplatin in advanced non-small cell lung cancer. Heo SJ, Jung I, Lee CK, Kim JH, Lim SM, Moon YW, Shim HS, Jeong J, Kim JH, **Kim HR***, Cho BC*. **Cancer Chemother Pharmacol. 2016 Jan 25. (Co-correspondence)**
97. Exome sequencing reveals recurrent REV3L mutations in cisplatin-resistant squamous cell carcinoma of head and neck. Huang KK, Jang KW, Kim S, Kim HS, Kim SM, Kwon HJ, **Kim HR**, Yun HJ, Ahn MJ, Park KU, Ramnarayanan K, McPherson JR, Zhang S, Rhee JK, Vettore AL, Das K, Ishimoto T, Kim JH, Koh YW, Kim SH, Choi EC, Teh BT, Rozen SG, Kim TM, Tan P, Cho BC. **Sci Rep. 2016**
98. Pharmacogenetic analysis of advanced non-small-cell lung cancer patients treated with first-line paclitaxel and carboplatin chemotherapy. Park HS, Lim SM, Shin HJ, Cho A, Shin JG, Lee MG, **Kim HR**, Kim JH, Cho BC. **Pharmacogenet Genomics. 2016**

99. A Case of ALK-Rearranged Adenocarcinoma with Small Cell Carcinoma-Like Transformation and Resistance to Crizotinib. Cha YJ, Cho BC, **Kim HR**, Lee HJ, Shim HS. **J Thorac Oncol.** 2015
100. Hyo Song Kim, Sung-Moo Kim, Hyunki Kim, Kyoung-Ho Pyo, Jong-Mu Sun, Myung-Ju Ahn, Keunchil Park, Bhumsuk Keam, Nak-Jung Kwon, Hwan Jung Yun, Hoon-Gu Kim, Ik-Joo Chung, Jong Seok Lee, Kyung Hee Lee, Dae Joon Kim, Chang Geol Lee, Jin Hur, Hyunsoo Chung, Jun Chul Park, Sung Kwan Shin, Sang Kil Lee, **Hye Ryun Kim**, Yong Wha Moon, Yong Chan Lee, Joo Hang Kim, Soonmyung Paik and Byoung Chul Cho. Phase II clinical and exploratory biomarker study of dacomitinib in recurrent and/or metastatic esophageal squamous cell carcinoma. **Oncotarget.** 2015.
101. **Hye Ryun Kim**, Hyo Jin Park, and Sang-Jun Ha. PD-1: Dual guard for immunopathology. **Oncotarget.** 2015
102. Lim SM, Chung WY, Nam KH, Kang SW, Lim JY, Kim HG, Shin SH, Sun JM, Kim SG, Kim JH, Kang CW, **Kim HR***, Cho BC*. An open label, multicenter, phase II study of dovitinib in advanced thyroid cancer. **Eur J Cancer. (Co-correspondence)**
103. Park JS, Lee JS, Kim EY, Jung JY, Kim SK, Chang J, Kim DJ, Lee CY, Jung I, Kim JH, **Kim HR**, Moon YW, Kim HS, Cho BC, Shim HS. The frequency and impact of FGFR1 amplification on clinical outcomes in Korean patients with small cell lung cancer. **Lung Cancer**
104. Chon HJ*, **Kim HR***, Shin E, Kim C, Heo SJ, Lee CK, Park JK, Noh SH, Chung HC, Rha SY. The Clinicopathologic Features and Prognostic Impact of ALK Positivity in Patients with Resected Gastric Cancer. **Ann Surg Oncol. (Co-first author)**
105. Lee CK, Jung M, Choi HJ, **Kim HR**, Kim HS, Roh MR, Ahn JB, Chung HC, Heo SJ, Rha SY, Shin SJ. Results of a Phase II Study to Evaluate the Efficacy of Docetaxel and Carboplatin in Metastatic Malignant Melanoma Patients who Failed First-line Therapy Containing Darcabazine. **Cancer Res Treat**
106. Kim KH, Cho BC, Lee CG, **Kim HR**, Suh YG, Kim JW, Choi C, Baek JG, Cho J. Hippocampus-Sparing Whole-Brain Radiotherapy and Simultaneous Integrated Boost for Multiple Brain Metastases From Lung Adenocarcinoma: Early Response and Dosimetric Evaluation. **Technol Cancer Res Treat** 2015
107. Kim HS, Lee SE, Bae YS, Kim DJ, Lee CG, Hur J, Chung H, Park JC, Jung da H, Shin SK, Lee SK, Lee YC, **Kim HR**, Moon YW, Kim JH, Shim YM, Jewell SS, Kim H, Choi YL, Cho BC. Fibroblast growth factor receptor 1 gene amplification is associated with poor survival in patients with resected esophageal squamous cell carcinoma. **Oncotarget** 2015

108. Kim HS, Kwon HJ, Jung I, Yun MR, Ahn MJ, Kang BW, Sun JM, Kim SB, Yoon DH, Park KU, Lee SH, Koh YW, Kim SH, Choi EC, Koo DH, Sohn JH, Kim B, Kwon NJ, Yun HJ, Lee MG, Lee JH, Kim TM, **Kim HR**, Kim JH, Paik S, Cho BC. Phase II clinical and exploratory biomarker study of dacomitinib in patients with Recurrent and/or metastatic squamous cell carcinoma of head and neck. **Clin Cancer Res** 2015
109. Cha YJ, Lee JS, **Kim HR**, Lim SM, Cho BC, Lee CY, Shim HS. Screening of ROS1 rearrangements in lung adenocarcinoma by immunohistochemistry and comparison with ALK rearrangements. **PLoS One** 2014
110. Kim MH, **Kim HR**, Cho BC, Bae MK, Kim EY, Lee CY, Lee JS, Kang DR, Kim JH. Impact of cigarette smoking on response to epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors in lung adenocarcinoma with activating EGFR mutations. **Lung Cancer** 2014
111. Ahn JW, Kim HS, Yoon JK, Jang H, Han SM, Eun S, Shim HS, Kim HJ, Kim DJ, Lee JG, Lee CY, Bae MK, Chung KY, Jung JY, Kim EY, Kim SK, Chang J, **Kim HR**, Kim JH, Lee MG, Cho BC, Lee JH, Bang D. Identification of somatic mutations in EGFR/KRAS/ALK-negative lung adenocarcinoma in never- smokers. **Genome Med.** 2014
112. Chang H, Shin SK, Cho BC, Lee CG, Kim CB, Kim DJ, Lee JG, Hur J, Lee CY, Bae MK, **Kim HR**, Lee SK, Park JC, Lee H, Kim HI, Chung H, Cha J, Lee YC, Kim JH. A prospective phase II trial of S-1 and cisplatin-based chemoradiotherapy for locoregionally advanced esophageal cancer. **Cancer Chemother Pharmacol** 2014
113. **Kim HR**, Cho BC, Shim HS, Lim SM, Kim SK, Chang J, Kim DJ, Kim JH. Prediction for response duration to epidermal growth factor receptor-tyrosine kinase inhibitors in EGFR mutated never smoker lung adenocarcinoma. **Lung Cancer** 2014
114. Kim MH, Shim HS, Kang DR, Jung JY, Lee CY, Kim DJ, Lee JG, Bae MK, **Kim HR**, Lim SM, Kim EY, Park JS, Chung KY, Kim HJ, Kim JH, Cho BC. Clinical and prognostic implications of ALK and ROS1 rearrangements in never-smokers with surgically resected lung adenocarcinoma. **Lung Cancer** 83(3):389-95. 2014 Mar
115. Kim KH, Kim HY, **Kim HR**, Sun JM, Lim HY, Lee HJ, Lee S, Bae WK, Rha SY. Efficacy and toxicity of sunitinib in patients with metastatic renal cell carcinoma with renal insufficiency. **Eur J Cancer** 2014 Mar
116. **Kim HR**, Park HS, Kwon WS, Lee JH, Tanigawara Y, Lim SM, Kim HS, Shin SJ, Ahn JB, Rha SY. Pharmacogenetic determinants associated with sunitinib-induced toxicity and ethnic difference in Korean metastatic renal cell carcinoma patients. **Cancer Chemother Pharmacol** 2013

117. Jeong JH, Cho BC, Shim HS, **Kim HR**, Lim SM, Kim SK, Chung KY, Ul Islam SM, Song JJ, Kim SY, Kim JH. Transglutaminase 2 expression predicts progression free survival in non-small cell lung cancer patients treated with epidermal growth factor receptor tyrosine kinase inhibitor. **J Korean Med** 2013
118. **Kim HR**, Lim SM, Kim HJ, Hwang SK, Park JK, Shin E, Bae MK, Ou SH, Wang J, Jewell SS, Kang DR, Soo RA, Haack H, Kim JH, Shim HS, Cho BC. The frequency and impact of ROS1 rearrangement on clinical outcomes in never smokers with lung adenocarcinoma. **Ann Oncol** 2013
119. **Kim HR**, Ahn JR, Lee JG, Bang DH, Ha SJ, Hong YK, Kim SM, Nam KC, Rha SY, Soo RA, Riely GJ, Kim JH, Cho BC. The impact of cigarette smoking on the frequency of and qualitative differences in KRAS mutations in Korean patients with lung adenocarcinoma. *Yonsei Med J* 54(4):865-74. 2013 Jul
120. Lee JS, **Kim HR**, Lee CY, Shin M, Shim HS EGFR and TTF-1 gene amplification in surgically resected lung adenocarcinomas: clinicopathologic significance and effect on response to EGFR-tyrosine kinase inhibitors in recurred cases. *Ann Surg Oncol* 2013
121. Lim S, Cho BC, Jung JY, Kim GM, Kim SH, **Kim HR**, Kim HS, Lim SM, Park JS, Lee JH, Kim D, Kim EY, Park MS, Kim YS, Kim SK, Chang J, Kim JH Phase II study of camtobell inj. (belotecan) in combination with cisplatin in patients with previously untreated, extensive stage small cell lung cancer. *Lung Cancer* 2013
122. Lim SM, **Kim HR**, Shim HS, Soo RA, Cho BC. Role of FGF receptors as an emerging therapeutic target in lung squamous cell carcinoma. *Future Oncol.* 2013
123. Kim SH, Shim HS, Cho J, Jeong JH, Kim SM, Hong YK, Sung JH, Ha SJ, **Kim HR**, Chang H, Kim JH, Tania C, Cho BC. A phase I trial of gefitinib and nimotuzumab in patients with advanced non-small cell lung cancer (NSCLC). *Lung Cancer.* 2013
124. Chan Woo Kang, Kang Won Jang, Jinyoung Sohn, Sung-Moo Kim, Kyoung-Ho Pyo, Hwan Kim, Mi Ran Yun, Han Na Kang, **Hye Ryun Kim**, Sun Min Lim, Yong Wha Moon, Soonmyung Paik, Joo Hang Kim and Byoung Chul Cho. Anti-tumor activity and acquired resistance mechanism of Dovitinib (TKI258) in RET rearranged lung adenocarcinoma. **Mol Cancer Ther** 2015
125. Kim HS, **Kim HR**, Kim GM, Kim HS, Koh YW, Kim SH, Choi EC, Hong YK, Sung JH, Kim SM, Kim JH, Cho BC. The efficacy and toxicity of S-1 and cisplatin as first-line chemotherapy in recurrent or metastatic head and neck squamous cell carcinoma. **Cancer Chemother Pharmacol.** 2012

126. Chang H, Kim SH, Cho BC, Yoon SH, **Kim HR**, Lee CG, Kim JH. Phase II study of cisplatin with irinotecan as induction chemotherapy followed by chemoradiotherapy for unresectable stage III non-small cell lung cancer. *Anticancer Res.* 2012 Aug;32(8):3515-21
127. **Hye Ryun Kim**, Byung Soh Min, Jin Soo Kim, Sang Jun Shin, Jung Bae Ahn, Jae Kyung Rho, Nam Kyu Kim, Sun Young Rha. Efficacy of Oxaliplatin-Based Chemotherapy in Curatively Resected Colorectal Cancer with Liver Metastasis *Oncology* 2011
128. **Hye Ryun Kim**, Seong Ha Cheon, Sun Young Rha, Soohyeon Lee, Kwang-Hyub Han, Chae Yoon Chon, Jong Doo Lee, Jin Sil Sung, Hyun Cheol Chung. Treatment of recurrent hepatocellular carcinoma after liver transplantation. *Asia Pac J Clin Oncol* 2011
129. **Hye Ryun Kim**, Shim Hyo Sup, Chung Jin Haeng, Lee Young Joo, Hong Yoon Kyoung, Rha Sun Young, Kim SH, Ha Sang Joon, Kim SK, Chung Kyoung Young, Soo Ross, Kim Joo Hang, Cho Byoung Chul. Distinct clinical features and outcomes in never-smokers with non small cell lung cancer who harbor EGFR or KRAS mutations or ALK rearrangement. *Cancer* 2012
130. Shin Sang Joon, Jung Min Kyu, Jeung Hei-Cheul, **Hye Ryun Kim**, Rha Sun Young, Roh Jae Kyoung, Chung Hyun Cheol, Ahn Joong Bae. A phase I pharmacokinetic study of TSU-68 (a multiple tyrosine kinase inhibitor of VEGFR-2, FGF and PDGF) in combination with S-1 and oxaliplatin in metastatic colorectal cancer patients previously treated with chemotherapy. *Invest New Drugs* 2011
131. Shin Sang Joon, Ahn Joong Bae, Park KS, Lee YJ, Hong YS, Kim TW, **Hye Ryun Kim**, Rha Sung Young, Roh Jae Kyoung, Kim DH, Kim C, Chung HC. A Phase Ib pharmacokinetic study of the anti-angiogenic agent CKD-732 used in combination with capecitabine and oxaliplatin (XELOX) in metastatic colorectal cancer patients who progressed on irinotecan-based chemotherapy. *Invest New Drugs* 2010
132. **Hye Ryun Kim**, Seong Ha Cheon, Jung Ryun Ahn, Hei-Cheul Jeung, Sung Sook Lee, Hyun Cheol Chung, Kwang-Hun Lee, Sung Hoon Noh, Sun Young Rha. Efficacy and Feasibility of Radiofrequency Ablation for Liver Metastases from Gastric Adenocarcinoma. *Int J Hyperthermia* 2010
133. Chon Hong Jae, Sun Young Rha, Im CK, Chan Kim, Hong MH, **Hye Ryun Kim**, Jung Ryun Ahn, Sung Hoon Noh, Hyun Cheol Chung, Hei-Cheul Jeung. Docetaxel versus paclitaxel combined with 5-FU and leucovorin in advanced gastric cancer: combined analysis of two phase II trials. *Cancer Res Treat* 2009

134. **Hye Ryun Kim**, Donghoon Choi, Joo Won Chung, Young Nam Youn, Chi Young Shim. Tension pneumopericardium after removal of pericardiocentesis drainage catheter. *Cardiology J* 2009
135. **Hye Ryun Kim**, Sun Young Rha, Seong Ha Cheon, Jae Kyung Rho, Park Young Nyun, Yoo Nae Choon. Clinical features and treatment outcomes of advanced stage primary hepatic angiosarcoma. **Ann Oncol** 2009
136. Jung Ryun Ahn, Minkyu Jung, Chan Kim, Min Hee Hong, Hong Jae Chon, **Hye Ryun Kim**, Hei-Cheul Jeung, Woo Jin Hyung, Sung Sook Lee, Hyun Cheol Chung, Sung Hoon Noh, Sun Young Rha. Prognosis of pN3 Stage Gastric Cancer. **Cancer Res Treat** 2009
137. Chan Kim, Eunah Shin, Soojung Hong, Hong Jae Chon, **Hye Ryun Kim**, Jung Ryun Ahn, Min Hee Hong, Woo Ick Yang, Jae Kyung Roh, Sun Young Rha. Clinical Value of Ezrin Expression in Primary Osteosarcoma. **Cancer Res Treat** 2009
138. Seong Ha Cheon, Sun Young Rha, Hei-Cheul Jeung, C.-K. Im, S. H. Kim, **Hye Ryun Kim**, Jung Bae Ahn, Jae Kyung Rho, Sung Hoon Noh, Hyun Cheol Chung. Survival benefit of combined curative resection of the stomach (D2 resection) and liver in gastric cancer patients with liver metastases. **Ann Oncol** 2008
139. **Hye Ryun Kim**, Byung Hoon Park, Ji Young Sohn, Ji Ye Chung, Jung Ryun Ahn, Yoon Suk Jeung, Joo Eun Yim, Joo Won Cheung, Jiye Moon, Moo Suk Park. A Case of Henoch-Shönlein Purpura Caused by Rifampin. **Tuberc Respir Dis** 2008
-